Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Provided By GlobeNewswire
Last update: May 12, 2025
CAMBRIDGE, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, today reported financial results for the first quarter ended March 31, 2025, and provided a corporate update.
Read more at globenewswire.com
